Riskpilot← Back to searchSign inGet full accessBIO PHARMA NORWAY AS
ASActiveOrg 985676771Brøsetekra 1, 7069 TrondheimWholesale of pharmaceutical and medical goods · NACE 4646Est. 20030 employees
Revenue 2024
NOK 1,9M
+23% vs 2023
EBITDA margin
3.6%
+148% vs 2023
Equity ratio
45.2%
Financial strength
Net profit 2024
NOK -61K
+70% vs 2023
| Revenue | NOK 1,9M | +23% |
| EBITDA | NOK 69K | +148% |
| Net profit | NOK -61K | +70% |
| Total assets | NOK 3,8M | +25% |
| Equity | NOK 1,7M | -3% |
| Employees | 0 | — |
Legal name
BIO PHARMA NORWAY AS
Org number
985676771
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
12. mai 2003
Share capital
NOK 136 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap eller daglig leder alene.
Company purpose
Handel, markedsføring og produksjon av helseprodukter og hva om står i forbindelse med dette, herunder å delta i andre selskap.
Address
Brøsetekra 1, 7069 Trondheim
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 829 | 1 799 | 1 665 | 1 558 | 1 924 |
| Staff expenses | −28 | −53 | −55 | −68 | −54 |
| EBITDA | 73 | 267 | 40 | −146 | 69 |
| Depreciation & amort. | −16 | −0 | −51 | −51 | −107 |
| EBIT | 58 | 267 | −11 | −197 | −38 |
| Net financials | 13 | 8 | 7 | 8 | −24 |
| Profit before tax | 71 | 275 | −4 | −189 | −61 |
| Tax | 16 | −0 | −4 | 14 | −0 |
| Net profit | 55 | 275 | −0 | −203 | −61 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 296 | 3 486 | 2 073 | 3 027 | 3 778 |
| Equity | 1 973 | 1 973 | 1 972 | 1 769 | 1 708 |
| Long-term debt | 0 | 0 | 0 | 1 121 | 1 978 |
| Short-term debt | 1 323 | 1 513 | 101 | 137 | 92 |
| Total debt | 1 323 | 1 513 | 101 | 1 258 | 2 070 |
EBITDA margin
3.6%
This company
15.8%
Market median
-77% vs market
20202024
Equity ratio
45.2%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
-3.6%
This company
18.4%
Market median
-120% vs market
20202024
Net profit margin
-3.2%
This company
8.1%
Market median
-140% vs market
20202024
Asset turnover
0.51×
This company
1.12×
Market median
-54% vs market
20202024
Debt / equity
1.21×
This company
0.62×
Market median
-95% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GS Chief Executive Officer | Chief Executive Officer | 2012 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2007 | |
| Chairman | 2007 | |
| Board of Directors | 2007 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Guts Holding As
BIO PHARMA NORWAY AS Board members of BIO PHARMA NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gunnar Sæther | Chief Executive Officer | 0 companies |
| Siri Nielsen Sæther | Board of Directors | 0 companies |
| Tom Benestad | Chairman | 0 companies |
| Terje Sæther | Board of Directors | 0 companies |